FTI TechnipFMC Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 65
Relative Profitability: Rel. Profitability: 76

EPS in 2026 (TTM): $2.93

Last Report Period Date: Jun 30, 2026

As of August 2026, FTI's trailing twelve months (TTM) EPS stands at $2.93, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of $2.34, which represents an increase compared to its EPS of $1.96 in 2024. FTI reported an EPS of $0.92 for the quarterly report ending on Jun 30, 2026.

FTI earnings history

Historical annual and quarterly earnings per share (EPS) data for TechnipFMC
EPS (TTM)
$2.93
EPS Growth YoY (Quarterly)
41.5%
EPS (Quarterly)
$0.92
EPS Growth (Quarterly)
41.5%

For 2025, TechnipFMC's EPS was $2.34, an increase of 19.4% from $1.96 in 2024. For the quarter ending Jun 30, 2026, the EPS was $0.92, showing a 41.5% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of June 2026 is $2.93. In 2024, the annual EPS was $1.96, showing an increase of 1,407.7% from 2023.

FTI earnings chart

FTI EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
41.5%
EPS growth YoY
19.4%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Over the last 12 months, TechnipFMC has registered an EPS growth of 41.5% (YoY, quarterly). A 10-year view shows that FTI has seen an average EPS growth of 33.5% per year.

FTI Earnings Waterfall

Breakdown of revenue, profit and net income for TechnipFMC

FTI Earnings vs Peers

What are the earnings of FTI compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
FTI TechnipFMC plc 23.79 19.4% N/A N/A
SLB SLB 23.81 -24.2% -0.7% N/A
INVX Innovex International Inc 37.38 -57.1% -16.4% N/A
GE General Electric Company 42.91 35.8% 447.4% 12.1%
NOV NOV Inc 72 -75.9% -0.8% N/A
OIS Oil States International Inc N/A -933.3% N/A N/A
FET Forum Energy Technologies Inc N/A 92.6% N/A N/A
BOLT Bolt Biotherapeutics Inc N/A 46% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.